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Background: Neoadjuvant stereotactic body radiotherapy (SBRT) has potential applicability in the management of
borderline resectable and locally-advanced pancreatic adenocarcinoma. In this series, we report the pathologic out-
comes in the subset of patients who underwent surgery after neoadjuvant SBRT.
Methods: Patients with borderline resectable or locally-advanced pancreatic adenocarcinoma who were treated
with SBRT followed by resection were included. Chemotherapy was to the discretion of the medical oncologist and
preceded SBRT for most patients.
Results: Twelve patients met inclusion criteria. Most (92%) received neoadjuvant chemotherapy, and gemcitabine/
capecitabine was most frequently utilized (n = 7). Most were treated with fractionated SBRT to 36 Gy/3 fractions
(n = 7) and the remainder with single fraction to 24 Gy (n = 5). No grade 3+ acute toxicities attributable to SBRT
were found. Two patients developed post-surgical vascular complications and one died secondary to this. The mean
time to surgery after SBRT was 3.3 months. An R0 resection was performed in 92% of patients (n = 11/12). In 25%
(n = 3/12) of patients, a complete pathologic response was achieved, and an additional 16.7% (n = 2/12)
demonstrated <10% viable tumor cells. Kaplan-Meier estimated median progression free survival is 27.4 months.
Overall survival is 92%, 64% and 51% at 1-, 2-, and 3-years.
Conclusions: This study reports the pathologic response in patients treated with neoadjuvant chemotherapy and
SBRT for borderline resectable and locally-advanced pancreatic cancer. In our experience, 92% achieved an R0
resection and 41.7% of patients demonstrated either complete or extensive pathologic response to treatment. The
results of a phase II study of this novel approach will be forthcoming.
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Pancreatic cancer is the fourth leading cause of death from
cancer in both men and women in the United States [1]. It
is a highly aggressive entity with approximately 40% pre-
senting as locally-advanced but unresectable disease and
an additional 40% presenting with metastatic disease [2].
Despite intensive efforts with chemotherapy and radiation* Correspondence: burtons@upmc.edu
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distribution, and reproduction in any mediumtherapy, surgical resection remains the only treatment
option associated with long-term survival [3].
Chemotherapy and radiation therapy have been ex-
plored in the adjuvant setting. The GITSG trial was the
only major clinical trial to demonstrate a survival bene-
fit for adjuvant chemoradiation [4]. However, this study
is routinely criticized for its small size, antiquated tech-
niques and split-course radiation delivery. Furthermore,
when attempted to be replicated by EORTC 40891, no
benefit to adjuvant chemoradiation was demonstrated.
Based upon this study and ESPAC-1, which does have antral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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effect of adjuvant chemoradiation, the use of adjuvant
radiation has fallen out of favor in Europe and is contro-
versial in North America [5,6]. Meanwhile, a number of
studies including CONKO-001 and RTOG 9704 began
to shed light that gemcitabine-based adjuvant chemo-
therapy may be more efficacious than previous regimens
[7,8]. However, it must be noted that the recent update
to ESPAC-3 found that adjuvant gemcitabine may be
equivalent to adjuvant 5FU [9].
Neoadjuvant therapy has a number of potential benefits
compared to adjuvant therapy. It may, in theory, eradicate
micrometastatic disease while potentially downsizing the
primary lesion to facilitate a margin negative (R0) resec-
tion. Many patients may never recover sufficiently to toler-
ate adjuvant therapy. Finally, patients can be selected for
surgery and those who develop metastatic disease during
the course of neoadjuvant therapy can be spared the mor-
bidity and mortality risks associated with a pancreatico-
duodenectomy. Neoadjuvant therapy was studied at MD
Anderson Cancer Center in a retrospective series of over
300 patients. This series lent evidence that induction
chemotherapy followed by concurrent chemo-radiation
for unresectable cancer improved progression-free survival
and median survival when compared to patients who
underwent chemoradiation alone [10].
Stereotactic Body Radiotherapy (SBRT) is particularly
promising for pancreatic cancer. SBRT enables the de-
livery of high doses to a small target in few fractions.
By completing radiotherapy in the span of one or two
weeks, the patient is potentially able to benefit from full
doses of chemotherapy without interruption, less toxicity,
and the ability to proceed to surgery faster. In this study,
we retrospectively analyzed patients with locally advanced
or borderline resectable pancreatic cancer who underwent
neoadjuvant therapy with SBRT and completed surgical
resection.Methods
Patient population
Patients with biopsy-proven borderline resectable or
locally-advanced pancreatic adenocarcinoma who were
treated with neoadjuvant SBRT from 2008–2011 and
completed surgical resection were included in this
retrospective analysis. Definitions for borderline resect-
ability and locally advanced disease were based on radio-
graphic criteria defined by Varadhachary [11]. All patients
were seen, evaluated, and followed by a pancreatico-biliary
surgeon, medical oncologist and radiation oncologist in
the Pancreas Multidisciplinary Clinic at the University
of Pittsburgh Cancer Institute. This study was con-
ducted under a formal Institutional Review Board ap-
proved protocol.Chemotherapy
Most patients in this series received neoadjuvant chemo-
therapy. The choice of chemotherapy was to the discre-
tion of the medical oncologist. Chemotherapy preceded
SBRT whenever possible.
Radiation therapy
For stereotactic localization, fiducial markers were re-
quired prior to SBRT. Two to three fiducial markers
were placed in or around the tumor. All patients under-
went a 4D-CT treatment simulation with a custom-
made relocatable Alpha Cradle® immobilization system
(Smithers Medical Products, North Canton, OH). Target
and critical structures (liver, small bowel, stomach, kid-
neys, and spinal cord) were contoured. The GTV was
defined as the tumor visible on the CT scan, and in
those with N1 disease, the nodes were not included in
the target. The GTV was expanded by 2 mm to form
the PTV.
The radiosurgical plan was devised to typically deliver
a dose of 24 Gy in a single fraction or 36 Gy in 3 frac-
tions. Patients treated during or before 2010 were
treated with a single fraction. The multidisciplinary
group chose to fractionate SBRT starting in 2011 to re-
duce the potential for toxicity. Recommended normal
tissue constraints guidelines for three fractions were as
follows: spinal cord <18 Gy, stomach <30 Gy, small
bowel <25 Gy, liver 15 Gy to <700 cm3, kidney 15 Gy to
<1/3 total volume. For single fraction treatment, the
small bowel maximum point dose was 18.5 Gy. Plans
were devised such that the prescription dose was the
isodose line encompassing >95% of the PTV. No more
than 20% of the PTV was to receive a dose >110% of the
prescription dose. No more than 2% of the PTV was to
receive <93% of the prescription dose. Patients were
treated on any of three radiosurgical platforms including
the Accuray CyberKnife® (Accuray Inc., Sunnyvale, CA) or
Varian Trilogy® or TrueBeam® (Varian Medical Systems
Inc., Palo Alto, CA).
All patients underwent motion-compensated treatment
when required as determined by motion of the target. On
the CyberKnife® platform, the Synchrony™ respiratory
tracking system was utilized. For those treated on Trilogy®
or TrueBeam®, the Real-time Position Management™
Respiratory Gating System (Varian Medical Systems,
Inc. Palo Alto, CA) was utilized when required.
Surgery
Follow-up CT imaging was obtained in all patients 10–
12 weeks after the completion of SBRT as was the
standard protocol at our institution. If there was no evi-
dence of distant metastasis and the malignancy appeared
technically resectable, surgical exploration and curative
resection was recommended. Surgery was performed by
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went either classical pancreaticoduodenectomy or pylorus
preserving pancreaticoduodenectomy for head tumors
and distal pancreatectomy for body/tail lesions. When
there was involvement of the celiac or hepatic artery, an
Appleby procedure may have been performed. When
required, vein reconstruction was also performed.
Pathology
All surgical pathology specimens were analyzed at the
same lab in the University of Pittsburgh Cancer Institute.
Negative margins were scored if there was at least a 1 mm
margin of benign tissue. All pathologic specimens were
re-reviewed and scored by an expert pathologist (AK).
Pathologic response after neoadjuvant therapy was scored
using the Evans’ criteria as detailed in Table 1 [12].
Statistical methods
All figures are reported as mean ± standard deviation ex-
cept when otherwise indicated. Kaplan-Meier survival
analysis was used to estimate overall survival (OS) and
progression free survival (PFS). Survival rates were cal-
culated from the date of biopsy. Acute toxicities were
defined as those occurring within 90 days of SBRT and
late toxicities were defined as those occurring thereafter.
SPSS® software version 18.0 (IBM Corp., Armonk, NY)
was used for statistical analysis.
Results
Patient characteristics
One-hundred and five patients were treated at our institu-
tion with SBRT for pancreatic cancer for primary or
definitive intent. Of these, twelve patients underwent sur-
gical resection after SBRT and thus met criteria for inclu-
sion in this retrospective series. The median age was 68
(range: 82–41 years) and 41.7% were male. All patients
were considered to have locally advanced (n = 5/12) or
borderline resectable (n = 7/12) disease as determined by
experienced pancreatic surgeons. Patients were evenly di-
vided between T3 (50%) and T4 (50%) stage. The majority
of patients were N0, but 41.7% had N1 disease.Table 1 Evans’ criteria for pathologic response following
neoadjuvant therapy
Grade Tumor regression
I <10% to no tumor cells destroyed
II IIa: 10-50% of tumor cells destroyed
IIb: 50-90% of tumor cells destroyed
III >90% of tumor cells destroyed
IIIM: sizable pools of cellular mucin
IV No viable tumor cells
IVM: Acellular pools of mucinChemotherapy
Most patients (91.7%) had neoadjuvant chemotherapy
following diagnosis and preceding SBRT. One patient did
not have neoadjuvant chemotherapy due to recent bone
marrow transplant for multiple myeloma. In this case,
single-agent gemcitabine was deferred to the adjuvant set-
ting. Among those who received neoadjuvant chemother-
apy, it was gemcitabine-based in the vast majority (90.9%)
and most received gemcitabine /capecitabine (n = 7/11).
Other neoadjuvant chemotherapy regimens included
gemcitabine/erlotinib, gemcitabine alone, FOLFIRINOX
and gemcitabine/Abaxane® followed by FOLFIRINOX.
Following surgery, the majority of patients (75%) did
receive additional chemotherapy in the adjuvant setting.
Stereotactic body radiotherapy
SBRT was delivered at a single site by experienced radi-
ation oncologists. Treatment was delivered on either the
CyberKnife® platform for 33% of the patients and the
remaining patients were treated on the Varian Trilogy™ or
TrueBeam™ platforms. Patients treated from 2008 – 2010
received a single fraction dose of 24 Gy (n = 5/12) while
those treated in 2011 typically received a hypofractionated
course of 36 Gy in 3 fractions (n = 6/12) and one received
30 Gy in 3 fractions (Figure 1). The mean target volume
was 16.6 cm3 (range: 5.1 – 44.6 cm3). Intensity modulated
radiosurgery plans typically involved 11–13 fields while
those on the CyberKnife® platform utilized 150–170
beams. Maximum spinal cord doses were 1.56 Gy (range:
1.0 – 1.8 Gy) for single fraction plans and 6.6 Gy (range:
1.3 – 10.2 Gy) for hypofractionated plans. Maximum
bowel doses were 13.7 Gy (range: 11.3 – 16.1 Gy) and
21.6 Gy (16.8 – 25.1 Gy) for single and multi-fraction
plans respectively. There were no acute grade 3 or higher
toxicities directly attributable to SBRT.
Surgery
The mean time to surgery following SBRT was 3.3 months
(range: 1.5 – 6.6 months). Vein reconstruction was
performed in 25% of cases. Postoperative complica-
tions included pseudoaneruysm, bradycardia, infection
and bleeding. There was one patient who suffered both
post-operative infection and bleeding in the postopera-
tive period and eventually succumbed to this. This was
felt to be a technical complication related to the sur-
gery and narrow vasculature and not related to SBRT.
However, two other patients developed pseudoaneur-
ysms which are thought to be related to SBRT. One pa-
tient, who underwent surgery 6.6 months following
SBRT, developed a pseudoaneurysm of the gastroduo-
denal artery in the absence of a pancreatic leak and re-
quired coiling. She recovered well from the procedure.
Another patient, who underwent surgery 4.5 months
after SBRT, developed a pseudoanerusym of the splenic
Figure 1 Treatment plan for a patient treated with SBRT to a dose of 36 Gy / 3 fractions following neoadjuvant chemotherapy
with gemcitabine/capecitabine.
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required multiple procedures approximately 6.5 months
following surgery, and eventually died of complications
related to this. After multidisciplinary review, the group
believes that these two vascular complications are re-
lated to a long interval between SBRT and definitive sur-
gical management.Pathology
Final pathology revealed that an R0 resection with at least
a 1 mm margin was achieved in the vast majority of pa-
tients (91.7%). There was only one patient who had a
positive margin and this patient had borderline resect-
able disease at diagnosis. All patients who underwent a
vein reconstruction achieved an R0 resection.
Three patients (25%) achieved a complete pathologic re-
sponse (pCR) to neoadjuvant therapy (Figure 2). These pa-
tients were treated with SBRT to 36 Gy in three fractions.
Two patients (16.7%) had >90% of tumor cells destroyed
and an additional two (16.7%) had > 50% tumor cell de-
struction when scored by Evans’ criteria (Table 2). Thus
41.7% of patients had at least 90% tumor cell destruction
in response to neoadjuvant therapy and a total of 58.3%
had at least 50% tumor cell destruction.Survival
Survival data is available with a median follow-up of
16.6 months (range: 10.5 – 54.5 months). Kaplan-Meier
estimated 1-, 2-, and 3-year OS is 92%, 64% and 51% re-
spectively (Figure 3). Kaplan-Meier estimated median
survival is 47.2 months and median PFS is 27.4 months.
Due to the small numbers in this study, subset analyses
correlating time to surgery and pathologic response and
pCR or R0 resection to outcome were not significant.
Discussion
Herein we present pathologic outcomes in a series of pa-
tients with locally advanced and borderline resectable
pancreatic cancer who underwent neoadjuvant SBRT.
We found that in this cohort, the pCR rate was 25% and
an additional 16.7% had an extensive response to therapy
with >90% tumor cell destruction. The estimated 1-, 2-,
and 3-year OS is 92%, 64% and 51%.
Most of the published studies analyzing SBRT have
been performed in locally advanced, unresectable dis-
ease. Memorial Sloan Kettering has reported outcomes
for patients treated in a phase II study with sequential
gemcitabine and SBRT approach (with chemotherapy
preceding and following SBRT) [13]. SBRT was delivered
as a single fraction of 25 Gy using the Varian Trilogy®
Figure 2 The same patient had a complete pathologic response following neoadjuvant chemotherapy and SBRT. Panel A is from the
pre-treatment fine needle aspiration and shows adenocarcinoma. Panel B demonstrates extensive fibrosis in the surgical resection post-treatment
with no evidence of invasive adenocarcinoma. The small nests of cells that are present within the dense fibrosis are all islets (*=cystically dilated
duct lined by PanIN-3). Inset shows higher magnification of the boxed area, including one islet and PanIN-3.
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ation requiring surgery (5%). Median survival was
11.8 months and 1-year survival was 50%. The same
group has previously reported a similar series of patients
receiving gemcitabine and a single fraction of 25 Gy of
SBRT delivered on the CyberKnife® platform [14]. Similar
outcomes were reported with 11.4 months median sur-
vival and 1-year survival of 50% was noted. Acute toxic-
ities included gastric outlet obstruction (6.3%). Late
gastrointestinal toxicities included duodenal perforation
and stricture (12.5%). Our institution has also reported a
series of SBRT for locally advanced, unresectable disease[15]. The vast majority of patients were treated with a sin-
gle fraction of 24 Gy. The rate of acute grade 3 or higher
toxicities was 1.4%. Median survival in this series was
10.3 months and 1-year OS was 41%. A Harvard series
assessing gemcitabine and fractionated SBRT (24 – 36 Gy)
in the same population revealed a 14% grade 3 toxicity
rate with MS of 14.3 months [16]. Finally, Stanford has re-
ported on 77 patients with unresectable disease receiving
single fraction of 25 Gy and demonstrated a 1-year rate of
freedom from local progression of 84%, 1-year PFS of 9%,
and 1-year OS from SBRT 21%. They report a 9% late
grade 3 or higher toxicity [17].
Table 2 Pathologic response following neoadjuvant therapy
Neoadjuvant chemotherapy Neoadjuvant SBRT (dose / fractions) Pathologic response (Evans’ criteria)
01 Gem./Cape. 36 Gy / 3 IV
02 Gem./Cape. 36 Gy / 3 IV
03 FOLFIRINOX, Gem./Abraxane 36 Gy / 3 IV
04 Gem./Erlotinib 24 Gy / 1 III
05 Gem./Cape. 24 Gy / 1 III
06 Gem. 24 Gy / 1 IIb
07 FOLFIRINOX 36 Gy / 3 IIb
08 N/A 36 Gy / 3 IIa
09 Gem./Cape. 36 Gy / 3 IIa
10 Gem./Cape. 24 Gy / 1 IIa
11 Gem./Cape. 24 Gy / 1 IIa
12 Gem./Cape. 30 Gy /3 IIa
25% of patients achieved a complete pathologic (pCR) response to neoadjuvant therapy (Evans’ grade: IV), and an additional 16.7% of patients had >90% tumor
cell destruction (Evans’ grade: III). In total, 58.3% of patients had at least 50% of tumor cell destruction (Evans’ Grade: IIb – IV). For those achieving pCR, SBRT dose
was 36 Gy in 3 fractions and neoadjuvant chemotherapy was gemcitabine-based. [Abbreviations: Gem Gemcitabine, Cape Capecitabine].
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and has come under scrutiny. The Danish group has re-
ported on a phase II study of SBRT for locally advanced
pancreatic cancer in which a central dose of 45 Gy in
three fractions was delivered [18]. They found that there
was a significant deterioration in performance status,
pain and nausea associated with SBRT within 2 weeks,
but most improved by 3 months. They found that 18%
(n = 4/22) suffered severe gastrointestinal ulceration or
mucositis and one had perforation of the stomach. TheFigure 3 Kaplan-Meier curves for progression-free survival (Panel A) a
was 27.4 months. The median overall survival is 47.2 months. Overall survivMayo Clinic undertook a dosimetric analysis of 47 pa-
tients undergoing abdominal SBRT to targets in proxim-
ity to hollow viscous organs [19]. A variety of dose and
fractionations were used, but the most common was
50 Gy/5 fractions. There were no acute grade 3 or higher
toxicities. Five late gastrointestinal toxicities were found,
but no dose correlation could be ascertained. This re-
port, taken in conjunction with the number of other re-
ports detailing pancreatic SBRT, demonstrates the
technique is feasible and can be performed with annd overall survival (Panel B). The median progression free survival
al is 92%, 64% and 51% at 1-, 2- and 3-years respectively.
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and in this report no acute grade 3 or higher toxicities
were seen. It is hypothesized that the late gastrointestinal
toxicity rate attributable to SBRT may be less frequent in
our approach since the distal stomach and duodenum,
which can stricture, ulcerate or perforate, is resected
shortly after SBRT. There were two patients who devel-
oped pseudoaneurysm in the post-operative period in the
absence of pancreatic leak. Thus we suspect this is related
to ischemic injury secondary to SBRT. In both these pa-
tients, the interval from SBRT to surgery was greater than
4 months. We now believe that a shorter interval may re-
duce the potential for toxicity. We have since modified
our protocol to obtain follow-up imaging 4 weeks follow-
ing SBRT with the goal of performing surgery with a
shorter interval from SBRT.
In the preoperative setting, two reports describe patients
treated with SBRT who underwent resection. An Italian
group studied patients with initially unresectable pancre-
atic cancer who underwent gemcitabine followed by SBRT
and resection when feasible. Of the 23 patients who were
enrolled on protocol, only two underwent resection. Both
had an R0 resection but both had positive peri-pancreatic
lymph nodes. One was found to a pCR in the primary site
and the other had a partial response. Moffitt has reported
on a large series of patients undergoing induction chemo-
therapy and SBRT for locally advanced and borderline re-
sectable disease [20]. Of those that completed surgery,
97% had an R0 resection and the pCR rate was 9.4%.
There are a number of studies reporting pathologic
outcomes following neoadjuvant chemotherapy with or
without conventionally fractionated radiation therapy.
A French group explored perioperative chemo-radiation
and found a pCR rate of 7.5% (n = 3/40) [21]. MD An-
derson Cancer Center has reported a phase II approach
with neoadjuvant chemotherapy and radiation therapy
and found a 2.7% pCR rate [22]. In a review of the ex-
perience at MD Anderson from 1995 – 2010, only 2.5%
of patients who underwent neoadjuvant therapy and
pancreatectomy achieved pCR. The authors concluded
that, while rare, pCR was associated with extended
survival [23].
There are limitations with our study as there are with all
retrospective reports. Of the 105 patients treated with
SBRT, only the twelve who completed both neoadjuvant
therapy and surgery were included in the study and for
survival analysis. Furthermore, the neoadjuvant approach,
by design, selects for patients who do not develop distant
metastases or extensive local progression that preclude
use of SBRT. Thus, survival estimates reported in this
series are expected to be higher than other reports. Finally,
since most patients received neoadjuvant chemotherapy
and SBRT, it is unknown if one of these modalities was
the primary effector of the pathologic response.Despite these limitations, however, this approach and
these results are certainly promising. We believe an ag-
gressive, tri-modality approach provides patients the great-
est chance for a durable response and potential cure.
Surgery has always remained the mainstay and those who
are able to have it performed certainly benefit [3]. Chemo-
therapy has also proven benefit in a number of trials and
is also an integral component of treatment. The role for
long course, external beam radiation therapy in pancreatic
cancer, however, remains nebulous. This approach allows
full, systemic doses of chemotherapy to be delivered
without interruption and allows the expeditious delivery
of high dose radiation therapy before definitive surgical
management.
Conclusions
In summary, we report our experience in a subset of
patients with locally advanced and borderline resect-
able pancreatic cancer who were treated with neoadju-
vant chemotherapy and SBRT followed by resection.
We found that this approach is safe and is tolerated
well. In our experience, 92% achieved an R0 resection
and 41.7% of patients demonstrated either complete or
extensive pathologic response to treatment. This is a
promising area for further exploration in this disease
site, and we currently have an ongoing phase II trial at
our institution exploring this approach.
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